Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 82 clinical trials
featured
A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer

A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer

breast cancer
cyclophosphamide
invasive breast cancer
doxorubicin
paclitaxel
  • 66 views
  • 03 Dec, 2020
  • 1 location
featured
A Phase II/III Randomized Trial Of Veliparib Or Placebo In Combination With Adjuvant Temozolomide In Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation

A Phase II/III Randomized Trial Of Veliparib Or Placebo In Combination With Adjuvant Temozolomide In Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation

temozolomide
glioblastoma
  • 164 views
  • 24 Nov, 2020
  • 1 location
featured
A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Screening Step) Lung-MAP Study

A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Screening Step) Lung-MAP Study

cancer
lung carcinoma
lung cancer
  • 28 views
  • 23 Nov, 2020
  • 1 location
Acupuncture for Peripheral Neuropathy Induced by Paclitaxel in Early Stage Breast Cancer

The present study aims to evaluate the effectiveness of acupuncture in the treatment of chemotherapy drug paclitaxel induced peripheral neuropathy in patients with early stage breast cancer

breast cancer
cancer
acupuncture
peripheral neuropathy
paclitaxel
  • 0 views
  • 24 Jan, 2021
  • 1 location
Tailored Second Line Treatment by Epidermal Growth Factor Receptor (EGFR) Mutation in Patients With Advanced Lung Adenocarcinoma

survival and progression free survival that indicated better efficacy for non-squamous patients treated with pemetrexed. These data supports that pemetrexed could be a preferable chemotherapy

lung adenocarcinoma
epidermal growth factor
cetuximab
erlotinib
EGFR
  • 9 views
  • 07 Nov, 2020
  • 1 location
Erlotinib and Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) After Failure of One Chemotherapy Regimen

administrated concomitantly, and therefore, it could improve the benefit of the combination therapy. This study will investigate if the intermittent treatment of a chemotherapy drug, such as

cancer chemotherapy
erlotinib
neutrophil count
secondary malignant neoplasm of liver
stage iv non-small cell lung cancer
  • 1 views
  • 07 Nov, 2020
  • 6 locations
A Phase II Trial of Combination Therapy With Celecoxib and Taxotere for the Treatment of Stage D3 Prostate Cancer

refractory prostate cancer. Celecoxib (Celebrex) is an FDA approved drug to treat arthritis. Taxotere (Docetaxel) is an FDA approved chemotherapy drug to treat certain forms of cancer. Both drugs

prostate specific antigen
gonadotropin
docetaxel
gonadorelin
metastasis
  • 51 views
  • 07 Nov, 2020
  • 1 location
Drug Sensitivity Screening for Gastrointestinal Cancer

chemotherapy drug sensitivity test in order to: Compare the ex vivo Maximal Inhibition Index(MI) and Drug Sensitivity Index (DSI) with patient's Overall Response Rate (ORR) Provide

  • 0 views
  • 24 Jan, 2021
  • 1 location
Ribociclib in Combination With Everolimus and Dexamethasone in Relapsed ALL

This research study is evaluating a drug called ribociclib (LEE011) given in combination with everolimus and other standard of care chemotherapy drugs as a possible treatment for relapsed or refractory ALL. The names of the drugs involved in this study are: ribociclib everolimus dexamethasone

  • 13 views
  • 27 Jan, 2021
  • 9 locations
Trastuzumab Deruxtecan in Participants With HER2-mutated Metastatic Non-small Cell Lung Cancer (NSCLC)

progression during/after at least one regimen of prior anticancer therapy (second line or later) that must have contained a platinum-based chemotherapy drug.

  • 0 views
  • 18 Apr, 2021
  • 52 locations